Feb. 17, 2011 -- Drugs prescribed to prevent fractures in osteoporosis may do double duty, cutting a woman’s risk of colon cancer by more than half for those who take them for at least a year, a new study shows.
The study is the latest in a growing body of research suggesting that bisphosphonates, drugs that lower fracture risk by slowing bone breakdown and increasing bone mass, may also fight cancer.
A pair of studies published last year in the Journal of Clinical Oncology, one by the same group responsible for the colon cancer finding, found that bisphosphonate use was associated with about a 30% reduced risk of getting breast cancer.
“That was a bit of a surprise because these drugs were not thought to have effects on cancer cells per se,” says Mone Zaidi, MD, PhD, professor and director of The Mount Sinai Bone Program at Mount Sinai School of Medicine in New York. Zaidi is studying the effects of bisphosphonates on cancer cells in the lab, but he was not involved in the current research.
“These are new actions of old drugs, and I think it’s actually quite a dramatic action of a widely used drug in osteoporosis that could have potential implications in cancer,” Zaidi says. “This study has profound implications.”
But other experts, as well as the study’s researchers, urged caution, noting that the study was powered only to demonstrate an association, not an action.
The researchers could not rule out, for example, that women who were motivated to take drugs to prevent fractures weren’t similarly motivated to take better care of their overall health, which might also have reduced their risk of cancer, says Rowan T. Chlebowski, MD, PhD, chief of medical oncology and hematology at the David Geffen School of Medicine at UCLA. “It’s still a question,” he tells WebMD.
Chlebowski is analyzing data from the Women’s Health Initiative study to see if he might also find ties between bisphosphonates and reduced risk of colon cancer. He was not involved in the current research.